We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Advanced Melanoma

Journal Scan / Research · September 15, 2022

Mocetinostat With Ipilimumab and Nivolumab for Unresectable Stage III/IV Melanoma

Melanoma research

 

Additional Info

Disclosure statements are available on the authors' profiles:

Melanoma research
Clinical and immune correlate results from a phase 1b study of the histone deacetylase inhibitor mocetinostat with ipilimumab and nivolumab in unresectable stage III/IV melanoma
Melanoma Res. 2022 Oct 01;32(5)324-333, JS Weber, BA Levinson, AS Laino, AC Pavlick, DM Woods

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading